Published • loading... • Updated
UCLA Researchers Find Drug May Help Stop Rare Lung Cancer From Returning
Summary by Westside Current
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
UCLA Researchers Find Drug May Help Stop Rare Lung Cancer From Returning
A landmark UCLA-led clinical trial reveals that the targeted cancer drug selpercatinib reduces the risk of rare RET fusion-positive lung cancer returning by 83%. Presented at ASCO 2026, the LIBRETTO-432 study proves 92% of early-stage patients remained cancer-free after two years. Discover how this breakthrough establishes a new standard for adjuvant targeted therapy.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
